Home page  |  Help  |  Clear
English  |  French
 Search  |  Categories  |  Titles A-Z  |  Countries  |  Compare countries  |  Index  
Full TOC
Expand Document
Expand Chapter
Preferences

close this bookNational Guidelines for the Clinical Management of HIV/AIDS - Tanzania (NACP; 2005; 131 pages)
View the documentLIST OF ABBREVIATIONS
View the documentACKNOWLEDGEMENTS
View the documentFOREWORD
Open this folder and view contentsCHAPTER 1: INTRODUCTION
Open this folder and view contentsCHAPTER 2: ORGANIZATION OF HIV/AIDS CARE AND TREATMENT
Open this folder and view contentsCHAPTER 3: HIV/AIDS PREVENTION
Open this folder and view contentsCHAPTER 4: PROTECTIVE MEASURES AGAINST HIV TRANSMISSION
Open this folder and view contentsCHAPTER 5: LABORATORY TESTS IN HIV/AIDS
Open this folder and view contentsCHAPTER 6: HIV/AIDS AND PREGNANCY
Open this folder and view contentsCHAPTER 7: PEDIATRIC HIV/AIDS AND RELATED CONDITIONS
Open this folder and view contentsCHAPTER 8: COMMUNITY AND HOME BASED CARE FOR PEOPLE LIVING WITH HIV/AIDS (PLHA)
Open this folder and view contentsCHAPTER 9: COUNSELLING RELATED TO HIV-TESTING AND TREATMENT ADHERENCE
Open this folder and view contentsCHAPTER 10: MANAGEMENT OF COMMON SYMPTOMS AND OPPORTUNISTIC INFECTIONS IN HIV/AIDS
Open this folder and view contentsCHAPTER 11: MANAGEMENT OF MENTAL HEALTH PROBLEMS IN HIV/AIDS
Open this folder and view contentsCHAPTER 12: MANAGEMENT OF HIV INFECTED PATIENTS USING ANTIRETROVIRAL DRUGS
Open this folder and view contentsCHAPTER 13: ARV THERAPY IN INFANTS AND CHILDREN
close this folderCHAPTER 14: USE OF ARVS IN SPECIAL CIRCUMSTANCES
close this folder14.1 People with tuberculosis disease and HIV co-infection
View the document14.1.1 Patient presents with TB before commencing ART
Open this folder and view contents14.2 Post Exposure Prophylaxis-(PEP)
Open this folder and view contents14.3 HIV PEP in men and women who have been raped/sexually assaulted
Open this folder and view contentsCHAPTER 15: HIV/AIDS AND NUTRITION
Open this folder and view contentsCHAPTER 16: MANAGEMENT OF ANTIRETROVIRAL MEDICINES
Open this folder and view contentsCHAPTER 17: CERTIFICATION OF HEALTHCARE FACILITIES AS CARE AND TREATMENT SITES
 

14.1 People with tuberculosis disease and HIV co-infection

Antiretroviral therapy is recommended for all patients with TB with a CD4 count <200 cells/mm³ and should be considered for TB patients with CD4 <350 cells/mm3. Treatment of TB remains a central priority for patient management and should not be compromised by ART. On the other hand, case fatality rates in many patients with TB during the first two months of TB treatment are high in particular when they present with advanced HIV disease, and ARV in this setting might be life-saving.

Patients with TB merit special consideration because co-management of HIV and TB is complicated by Rifampicin drug interactions with NNRTIs and PIs, pill burden, adherence and drug toxicity. Taking the available data into account, the first line treatment recommendation for patients with TB and HIV co-infection is (AZT or d4T) + 3TC+ EFZ. The 800 mg dose of EFZ achieves higher drug levels comparable to those seen in the absence of Rifampicin and thus may reduce the chance of HIV drug resistance, but also can increase the toxicity risk.

SQV/r in combination with the NRTI backbone is an alternative to EFZ although resistance is a clear risk with suboptimal adherence. ABC is another alternative to EFZ with the advantage of low pill burden, has no interaction with Rifampicin, and has the advantage of being able to be given to children under 3 years of age for whom appropriate EFZ dosing information is not yet available.

The following two scenarios summarise the management of patients co-infected with HIV and TB:

Patient develops tuberculosis while on antiretroviral therapy:

Antiretroviral therapy should be continued throughout TB treatment, with changes as follows:

First line drugs: Substitute Nevirapine for Efavirenz. If this is not possible (e.g. intolerant of Efavirenz or significant risk of falling pregnant), Nevirapine may be substituted with Abacavir or Saquinavir/ritonavir.

Second line drugs: Lopinavir/ritonavir should be changed to Saquinavir/ritonavir (dose: 400/400 mg every 12 hours - 3 extra caps of ritonavir). This should be continued until 2 weeks after completion of TB treatment, when the extra ritonavir can be stopped.

to previous sectionto next section

Please provide your feedback English  |  French